Plain-English translation of NCT07370909 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new oral medication called to see if it can help people with moderate-to-severe atopic dermatitis (eczema). Researchers want to find out whether this medication works better than a placebo (a fake pill) and whether it is safe to take. About 480 people will participate, and some will receive the medication while others receive a placebo to compare results.
Many people with moderate-to-severe eczema struggle to find treatments that work well for them. This medication belongs to a new class of drugs that work differently than current options, and this trial will help doctors understand if this treatment could offer relief to patients who need it most.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to take either (at one of two doses) or a placebo pill twice daily by mouth. You will attend multiple visits at a research center where doctors will examine your skin, ask you questions about your symptoms, and may perform blood tests or other assessments. The study will continue for a set period as the researchers track whether your eczema improves and monitor for any side effects.
AI-generated summary from trial data · Aug 28, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Shanghai Longwood Biopharmaceuticals Co., Ltd.
Collaborators
Tigermed Consulting Co., Ltd
Enrollment target
~480 participants
Started
March 2026
Primary completion
March 2028
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in August 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Barbara Chen
Peking University People's Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.